Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST
Condition(s):Connective Tissue Disease-Associated Pulmonary Arterial HypertensionLast Updated:February 6, 2024Terminated
Hide Studies Not Open or Pending
Condition(s):Connective Tissue Disease-Associated Pulmonary Arterial HypertensionLast Updated:February 6, 2024Terminated
Condition(s):Pulmonary Arterial HypertensionLast Updated:September 21, 2023Active, not recruiting
Condition(s):Pulmonary Arterial HypertensionLast Updated:September 28, 2015Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:April 9, 2014Terminated
Condition(s):Congenital Heart Disease; Pulmonary Arterial HypertensionLast Updated:October 18, 2022Active, not recruiting
Condition(s):Pulmonary Arterial HypertensionLast Updated:May 9, 2017Withdrawn
Condition(s):Pulmonary Arterial HypertensionLast Updated:December 27, 2023Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:January 13, 2015Completed
Condition(s):Pulmonary Artery HypertensionLast Updated:June 1, 2022Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:May 24, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.